JOHNSON & JOHNSONJNJ
JOHNSON & JOHNSON Financial Overview 2022–2025
A massive $7.0 billion reversal of talc litigation reserves in FY2025 significantly boosted earnings, but the critical narrative is Johnson & Johnson’s aggressive shedding of legacy assets to combat patent cliffs. The company is ruthlessly optimizing its portfolio, recently announcing plans to separate its Orthopaedics business shortly after the Kenvue spin-off. Consequently, total revenue appeared flat, moving from $93.8 billion in FY2021 to $94.2 billion in FY2025, as the company successfully replaced lost consumer income with high-margin medical volume.
Operational results highlight the urgent race to replace aging blockbusters with acquired growth. In FY2025, the Innovative Medicine segment grew 6.0% to $60.4 billion, absorbing a crushing 41.3% decline in STELARA revenue due to biosimilar competition. Simultaneously, the MedTech segment expanded 6.1% to $33.8 billion, bolstered by the integration of Shockwave and Abiomed. Despite rising leverage—net debt hit $27.8 billion to fund these deals—management raised the dividend for the 63rd consecutive year. Investors priced this transition at 18.8x earnings at the close of FY2025, with shares ending the year at $207.63.
Recent Developments (Q3 and Q4 2025)
Driven by the integration of strategic acquisitions, Q3 2025 sales rose 6.8% to $24.0 billion, while net earnings surged to $5.2 billion, nearly doubling from $2.7 billion in the prior year period. A notable 25.8% reduction in quarterly research and development expenses contributed to margin expansion as the company normalized spending after heavy upfront investment. The neuroscience portfolio gained immediate traction from the Intra-Cellular Therapies deal, with CAPLYTA sales bolstering the Innovative Medicine division alongside the cardiovascular contributions from Shockwave.
Bulls highlight the company’s ability to successfully monetize M&A targets to offset organic deceleration, reflected in an annual EPS of $11.03. Conversely, bears argue that slashing R&D budgets while relying on acquired assets creates long-term pipeline risk. By the February 2026 reporting date, the market re-rated shares to $240.86, implying a valuation of 21.8x earnings, a premium to the year-end multiple.
What to watch: Integration speed of the Orthopaedics separation; organic growth rates for CAPLYTA and Shockwave.
Rev
$94.19B
FY2025
NI
$26.80B
FY2025
EPS
$11.13
FY2025
OCF
$24.53B
FY2025
Year-over-year comparison from 10-K annual reports
Data from SEC Company Facts
Recent SEC Filings
JOHNSON & JOHNSON 8-K Report, Financial Results (Jan 21, 2026)
Johnson & Johnson (JNJ) has filed an 8-K report on January 21, 2026, to announce its financial results for the fourth quarter and full year ended December 28, 2025. The filing primarily directs investors to a press release (Exhibit 99.1) and supplementary data (Exhibit 99.2) for detailed sales and earnings information. While the 8-K itself does not contain the specific figures, these attached exhibits are the primary source for understanding the company's performance during the reported periods, including key financial metrics and operational achievements.
JOHNSON & JOHNSON 8-K Report, Financial Results (Oct 14, 2025)
Johnson & Johnson has filed an 8-K report highlighting key developments from its third quarter of 2025. The company announced its sales and earnings results for the quarter ended September 28, 2025, providing investors with updated financial performance data. This report also contains a significant strategic announcement regarding the company's intention to separate its Orthopaedics business. This separation could reshape JNJ's business portfolio and potentially unlock value for shareholders by allowing each segment to focus on its distinct growth opportunities.
JOHNSON & JOHNSON 8-K Report, Executive Changes (Sep 9, 2025)
Johnson & Johnson (JNJ) has announced a significant addition to its Board of Directors with the election of John Morikis, effective September 8, 2025. Mr. Morikis brings extensive leadership experience, having served as Executive Chairman, President, and CEO of The Sherwin-Williams Company from 2016 to 2024, with a career spanning nearly forty years at the company. His appointment is expected to enhance the Board's expertise, particularly given his significant tenure in executive roles. Mr. Morikis has been assigned to key committees, including the Audit Committee and the Compensation & Benefits Committee, indicating his immediate and strategic role within the company's governance. His compensation as a non-employee director will align with the standard practices outlined in JNJ's 2025 Proxy Statement.
JOHNSON & JOHNSON 8-K Report, Financial Results (Jul 16, 2025)
Johnson & Johnson (JNJ) has filed an 8-K report detailing its second-quarter financial results for the period ended June 29, 2025. The filing primarily references a press release and supplementary financial data, providing investors with key operational and financial performance metrics for the recently concluded quarter. This report is crucial for understanding the company's recent sales trends and earnings, which are vital indicators of its ongoing business health and strategic execution within its diverse segments, including pharmaceuticals, medical devices, and consumer health. Investors should review the attached exhibits for a comprehensive understanding of the company's performance against expectations and its trajectory for the remainder of the fiscal year. The provided documentation includes the press release announcing Q2 2025 results and unaudited comparative supplementary sales data along with condensed consolidated statements of earnings. These materials are essential for evaluating Johnson & Johnson's financial condition and operational results, allowing for comparisons to prior periods and potentially to industry benchmarks. The market will be closely watching these figures to assess the impact of various economic factors, competitive pressures, and the company's strategic initiatives on its bottom line and revenue generation.
JOHNSON & JOHNSON 8-K Report, Executive Changes (Jun 10, 2025)
Johnson & Johnson (JNJ) has announced a significant addition to its Board of Directors with the election of Daniel Pinto, effective July 1, 2025. Mr. Pinto, currently President of JPMorgan Chase and set to become Vice Chairman, brings extensive financial expertise to the board. His appointment to both the Audit Committee and the Compensation & Benefits Committee is noteworthy, suggesting a focus on financial oversight and executive compensation strategies. This appointment comes with the disclosure of a prior business relationship between JNJ and JPMorgan Chase, with JNJ paying approximately $39.2 million in fiscal year 2024 for various banking services. Investors should note that while Mr. Pinto's role at JPMorgan Chase involves services provided to JNJ, his director compensation will be in line with the Company's standard non-employee director compensation as outlined in its proxy statement. This move signals a potential strengthening of JNJ's governance and financial acumen.
View all 8-K filings →